Rheault Michelle N, Smoyer William E
Department of Pediatrics, University of Minnesota Masonic Children's Hospital, Minneapolis, Minnesota, USA.
Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio, USA.
Kidney Int. 2020 Jun;97(6):1104-1106. doi: 10.1016/j.kint.2020.01.030.
Gross et al. present results of the EARLY PRO-TECT trial, a randomized controlled trial of ramipril versus placebo in children with early-stage Alport syndrome. Although under-enrolled and not a positive trial in the traditional sense, EARLY PRO-TECT does provide strong supportive evidence for both long-term safety and a clinical benefit of early treatment with angiotensin-converting enzyme inhibitors in slowing the progression of both albuminuria and estimated glomerular filtration rate decline in children with Alport syndrome.
格罗斯等人公布了早期保护试验（EARLY PRO-TECT trial）的结果，这是一项针对早期阿尔波特综合征患儿的雷米普利与安慰剂的随机对照试验。尽管入组人数不足且并非传统意义上的阳性试验，但早期保护试验确实为血管紧张素转换酶抑制剂早期治疗在减缓阿尔波特综合征患儿蛋白尿进展和估计肾小球滤过率下降方面的长期安全性和临床益处提供了有力的支持证据。
